The Added Value of Transcatheter CT Hepatic Angiography (CTHA) Image Guidance in Percutaneous Thermal Liver Ablation: An Experts' Opinion Pictorial Essay

• Published in: Cancers Vol. 16; no. 6; p. 1193
• Main Authors: Puijk, Robbert S, Dijkstra, Madelon, van der Lei, Susan, Schulz, Hannah H, Vos, Danielle J W, Timmer, Florentine E F, Geboers, Bart, Scheffer, Hester J, de Vries, Jan J J, Smits, Maarten L J, Bruijnen, Rutger C G, Deschamps, Frédéric, de Baère, Thierry, Odisio, Bruno C, Meijerink, Martijn R
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.03.2024; MDPI
• Subjects: Ablation; Ablation (Surgery); Angiography; Cancer therapies; Catheters; Computed tomography; Contrast agents; Contrast media; CT imaging; Hemorrhage; Intubation; Liver; Liver cancer; Liver diseases; Malignancy; Medical equipment and supplies industry; Medical imaging; Medical test kit industry; Metastases; Metastasis; Opinion; Radiation; Tumors; Veins & arteries; Visualization; France; United States; Netherlands; United States > US; Germany; liver tumor; computed tomography (CT); quality control; CT hepatic arteriography (CTHA); image guidance; radiofrequency ablation (RFA); thermal liver ablation; microwave ablation (MWA)
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16061193

With the rapidly evolving field of image-guided tumor ablation, there is an increasing demand and need for tools to optimize treatment success. Known factors affecting the success of (non-)thermal liver ablation procedures are the ability to optimize tumor and surrounding critical structure visualization, ablation applicator targeting, and ablation zone confirmation. A recent study showed superior local tumor progression-free survival and local control outcomes when using transcatheter computed tomography hepatic angiography (CTHA) guidance in percutaneous liver ablation procedures. This pictorial review provides eight clinical cases from three institutions, MD Anderson (Houston, TX, USA), Gustave Roussy (Paris, France), and Amsterdam UMC (Amsterdam, The Netherlands), with the intent to demonstrate the added value of real-time CTHA guided tumor ablation for primary liver tumors and liver-only metastatic disease. The clinical illustrations highlight the ability to improve the detectability of the initial target liver tumor(s) and identify surrounding critical vascular structures, detect 'vanished' and/or additional tumors intraprocedurally, differentiate local tumor progression from non-enhancing scar tissue, and promptly detect and respond to iatrogenic hemorrhagic events. Although at the cost of adding a minor but safe intervention, CTHA-guided liver tumor ablation minimizes complications of the actual ablation procedure, reduces the number of repeat ablations, and improves the oncological outcome of patients with liver malignancies. Therefore, we recommend adopting CTHA as a potential quality-improving guiding method within the (inter)national standards of practice.